Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
91.35(c) 92.36(c) 98.82(c) 97.06(c) 95(c) Last
1 327 737 1 462 650 2 684 357 1 837 184 2 315 529 Volume
+3.23% +1.11% +6.99% -1.78% -2.12% Change
More quotes
Financials ($)
Sales 2017 1 278 M
EBIT 2017 -145 M
Net income 2017 -142 M
Debt 2017 72,9 M
Yield 2017 -
Sales 2018 1 486 M
EBIT 2018 -50,9 M
Net income 2018 -71,4 M
Debt 2018 50,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,0x
EV / Sales2018 11,2x
Capitalization 16 577 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
07/11 | 02:30pmSpecial Situation
More about the company
Surperformance© ratings of BioMarin Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL
06/23 BIOMARIN PHARMACEUTICAL : Technical Research on Biotech Equities -- Celsion, Sar..
06/22 BIOMARIN PHARMACEUTICAL : Announces Acceptance of Late Breaking Abstract at the ..
06/16 BIOMARIN PHARMACEUTICAL : Announces Acceptance of Late Breaking Abstract at the ..
06/12 BIOMARIN PHARMACEUTICAL INC : Change in Directors or Principal Officers, Amendme..
06/09 BIOMARIN PHARMACEUTICAL : European Commission Approves Brineura cerliponase alfa..
06/01 BIOMARIN PHARMACEUTICAL : European Commission Approves Brineura(TM) (cerliponase..
05/31 BIOMARIN PHARMACEUTICAL : to Attend Upcoming Investor Conference
05/09 BIOMARIN PHARMACEUTICAL : Biotech Stocks on Investors' Radar -- BioMarin Pharma,..
05/05 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) reported earnings of $0.20 per shar..
05/04 BIOMARIN PHARMACEUTICAL : FDA Approves Brineura cerliponase alfa for the Treatme..
More news
Sector news : Biopharmaceuticals
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Biopharmaceuticals
Latest Tweets
06/23Leerink Swann Raises BioMarin Pharmaceutical FY2018 Earnings Estimates to $0... 
06/23Traders Sell BioMarin Pharmaceutical Inc. $BMRN on Strength After Insider Sel.. 
06/22Tom Bowley: BioMarin Next In Line For Breakout Among Biotechs?  
06/22Tom Bowley: BioMarin Next In Line For Breakout Among Biotechs?  
06/22BioMarin Pharmaceutical Inc. $BMRN Director V Bryan Lawlis Sells 3,750 Shares.. 
More tweets
Qtime:72
News from SeekingAlpha
06/01 BioMarin's Brineura OK'd in EU
05/29 BIOTECH FORUM DAILY DIGEST : Headwinds Remain. Spotlight On MediWound
05/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2017 Update
05/19 BioMarin Pharmaceutical (BMRN) Bank of America Merrill Lynch 2017 Health Care..
05/12 Sangamo's Gene Therapy Gets Pfizer Stamp Of Approval
Advertisement
Chart BIOMARIN PHARMACEUTICAL
Duration : Period :
BioMarin Pharmaceutical Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 112 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..14.68%16 577
BIOGEN7.26%59 460
CSL LIMITED40.42%49 053
ALEXION PHARMACEUTICAL..3.04%28 310
GRIFOLS SA39.01%18 339
CHONGQING ZHIFEI BIOLO..--.--%4 287
More Results